16,555 Shares in Eli Lilly and Company $LLY Bought by Canandaigua National Trust Co of Florida

Key Points

• Canandaigua National Trust Co. of Florida acquired 16,555 Eli Lilly shares worth approximately $19.2 million, making LLY its largest portfolio holding. Institutional investors and hedge funds collectively own 82.53% of the stock.
• Eli Lilly shares rose 2.5% to $1,186.95, while the company reported quarterly earnings and revenue above analyst expectations, with revenue up 47.7% year over year.
• Wall Street maintains a broadly bullish view, with a consensus “Moderate Buy” rating and an average price target of $1,312.36, although the stock’s nearly 40 price-to-earnings ratio leaves it exposed to valuation concerns.

Canandaigua National Trust Co of Florida acquired a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,555 shares of the company's stock, valued at approximately $19,155,000. Eli Lilly and Company makes up about 10.8% of Canandaigua National Trust Co of Florida's portfolio, making the stock its largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Osbon Capital Management LLC bought a new position in Eli Lilly and Company during the 4th quarter worth about $25,000. Basso Capital Management L.P. bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $30,000. Maseco LLP boosted its position in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock worth $31,000 after buying an additional 28 shares during the period. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $39,000. Finally, Aventus Investment Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock worth $34,000 after buying an additional 27 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 2.5%

Shares of Eli Lilly and Company stock traded up $29.46 on Wednesday, reaching $1,186.95. 2,300,611 shares of the company were exchanged, compared to its average volume of 2,974,313. The company has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 39.83, a PEG ratio of 1.40 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65. The company has a 50-day moving average of $1,173.98 and a 200 day moving average of $1,092.69.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm's revenue was up 47.7% on a year-over-year basis. During the same period last year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Sanford C. Bernstein boosted their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a research note on Tuesday, July 14th. Jefferies Financial Group lifted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a report on Tuesday, June 9th. TD Cowen reissued a "buy" rating and issued a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Finally, UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,312.36.

Insider Activity

In other news, CAO Donald Zakrowski sold 2,000 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last quarter. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Healthcare was one of the market’s few strong sectors, with Eli Lilly among the leaders. The relative strength likely reflects continued investor preference for defensive healthcare companies and Lilly’s strong growth profile. Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
• Positive Sentiment: Analysts and commentators highlighted growth opportunities beyond Mounjaro and Zepbound, including oncology, immunology, neuroscience, insulin and other pipeline programs. This supports the view that Lilly’s long-term outlook is not dependent on a single obesity-drug franchise. Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound
• Positive Sentiment: Recent data for Lilly’s oral GLP-1 candidate Foundayo reportedly showed greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes. A successful oral product could broaden access and add another major growth driver, though the analysis still requires further validation. Foundayo Showed Better Results Than Oral Semaglutide in a New Analysis
• Positive Sentiment: Retatrutide, Lilly’s next-generation triple-hormone obesity candidate, was identified as a potentially underappreciated catalyst. Reported trial weight loss has exceeded Zepbound’s results, and a regulatory filing is expected in early 2027. Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026
• Neutral Sentiment: Investment commentary remains divided: Lilly’s rapid revenue and earnings growth support premium valuation, but the stock trades near 40 times trailing earnings, leaving limited room for execution errors. Eli Lilly: Impressive Growth, Questionable Valuation
• Negative Sentiment: The World Health Organization’s new childhood-obesity guidelines could increase scrutiny of obesity-drug use in younger patients and create additional regulatory or adoption hurdles for Lilly and Novo Nordisk. Eli Lilly and Novo Face New Pressure from WHO’s Childhood Obesity Guidelines

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.